Journal Watch · Cell Reports Medicine · 2026

Development and validation of a 5mC-based prognostic model for lung adenocarcinoma survival.

Compared with other reported LUAD prognostic models, MethPro-LUAD demonstrates better performance across cohorts, which offers valuable support for personalized postoperative treatment and follow-up, and warrants further prospective evaluation, highlighting its strong potential for clinical translation through feasible targeted assays.

Wu Y, Jiao Z, Xue J et al.Cell Reports Medicine3 min readPharma relevance 85/100

DOI: 10.1016/j.xcrm.2026.102727PMID: 41928513Study type: cohort / observational clinical study

TL;DR

Compared with other reported LUAD prognostic models, MethPro-LUAD demonstrates better performance across cohorts, which offers valuable support for personalized postoperative treatment and follow-up, and warrants further prospective evaluation, highlighting its strong potential for clinical translation through feasible targeted assays.

Key findings

  • In addition, the model's predictive performance remains robust in subgroups defined by age, sex, stage, and EGFR mutation and in disease-free survival analyses.
  • Compared with other reported LUAD prognostic models, MethPro-LUAD demonstrates better performance across cohorts, which offers valuable support for personalized postoperative treatment and follow-up, and warrants further prospective evaluation, highlighting its strong potential for clinical translation through feasible targeted assays.

Numbers at a glance (from the abstract)

N = 269N = 180N = 195N = 88N = 82N = 155

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

We develop MethPro-LUAD, a prognostic model based on eight 5-methylcytosine features, using TCGA-LUAD data (training, N = 269; testing, N = 180), and validate the model across two independent hospital cohorts (Beijing, N = 195; Nanjing, N = 88) and two external GEO datasets (N = 82 and N = 155) to ensure its generalizability and effectiveness. MethPro-LUAD stratifies patients into high- and low-risk groups, with high-risk individuals consistently showing significantly shorter overall survival across all cohorts.

Full abstract (original)

Background: Lung adenocarcinoma (LUAD) exhibits marked prognostic heterogeneity. Existing methylation-based prognostic models lack robustness, accuracy, or external validation, limiting their clinical utility.

What they did: We develop MethPro-LUAD, a prognostic model based on eight 5-methylcytosine features, using TCGA-LUAD data (training, N = 269; testing, N = 180), and validate the model across two independent hospital cohorts (Beijing, N = 195; Nanjing, N = 88) and two external GEO datasets (N = 82 and N = 155) to ensure its generalizability and effectiveness. MethPro-LUAD stratifies patients into high- and low-risk groups, with high-risk individuals consistently showing significantly shorter overall survival across all cohorts.

Results & conclusions: In addition, the model's predictive performance remains robust in subgroups defined by age, sex, stage, and EGFR mutation and in disease-free survival analyses. Compared with other reported LUAD prognostic models, MethPro-LUAD demonstrates better performance across cohorts, which offers valuable support for personalized postoperative treatment and follow-up, and warrants further prospective evaluation, highlighting its strong potential for clinical translation through feasible targeted assays.

Abstract © the authors / Cell Reports Medicine (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.xcrm.2026.102727 · PubMed 41928513.

Why it matters for pharma & biotech

  • Directly relevant to teams in targeted oncology / immuno-oncology — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: targeted oncology / immuno-oncology

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Cell Reports Medicine study find?

Compared with other reported LUAD prognostic models, MethPro-LUAD demonstrates better performance across cohorts, which offers valuable support for personalized postoperative treatment and follow-up, and warrants further prospective evaluation, highlighting its strong potential for clinical translation through feasible targeted assays.

What type of study is this?

It is a cohort / observational clinical study, published in Cell Reports Medicine in 2026. We develop MethPro-LUAD, a prognostic model based on eight 5-methylcytosine features, using TCGA-LUAD data (training, N = 269; testing, N = 180), and validate the model across two independent hospital cohorts (Beijing, N = 195; Nanjing, N = 88) and two external GEO datasets (N = 82 and N = 155) to ensure its generalizability and effectiveness.

Where can I read the original paper?

The original is at the publisher via DOI 10.1016/j.xcrm.2026.102727. PubMed ID: 41928513. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Wu Y, Jiao Z, Xue J et al.. Development and validation of a 5mC-based prognostic model for lung adenocarcinoma survival.. Cell Reports Medicine (2026). DOI: 10.1016/j.xcrm.2026.102727.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/development-and-validation-of-a-5mc-based-prognostic-model-for-lung-aden-102727/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides